Nautilus Biotechnology Inc Stock Price, News & Analysis

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced key presentations at upcoming scientific conferences. Co-founder Parag Mallick, Ph.D., will present at the XIV Annual Congress of the European Proteomics Association in Leipzig, Germany, on April 6, 2022, discussing their novel single-molecule proteomics analysis platform. Associate Director Greg Kapp, Ph.D., will present a poster at the AACR Annual Meeting in New Orleans, LA, on April 13, 2022, focusing on protein identification techniques. These engagements highlight Nautilus' commitment to advancing proteomics and its potential impact on human health.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has appointed Karen Akinsanya, Ph.D., as a new member of its Board of Directors. Dr. Akinsanya brings over 25 years of experience in drug discovery, development, and commercialization. Currently serving as President of R&D at Schrödinger, she has a strong background in clinical pharmacology and business development from her tenure at Merck Research Laboratories. Her leadership is expected to enhance Nautilus’ strategy for the commercialization of its innovative protein analysis platform aimed at improving human health.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its fourth quarter and fiscal year 2021 results, highlighting key achievements and financial metrics. The company completed a business combination with ARYA Sciences Acquisition Corp III, generating approximately $345.5 million. Operating expenses soared 221% to $50.5 million, while net loss widened to $50.3 million from $15.6 million year-over-year. Nautilus announced collaborations with Amgen and MD Anderson, and a strategic partnership with Abcam. As of December 31, 2021, cash and investments totaled $362.1 million, supporting ongoing development.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually in the 42^nd Annual Cowen Health Care Conference on March 7^th, 2022. The presentation is scheduled for 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties can access the live and archived webcast through Nautilus’ website.

Headquartered in Seattle, Nautilus is focused on developing a cutting-edge platform for detailed protein analysis, aiming to advance the field of proteomics and its applications in human health and medicine.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its financial results for Q4 and the full year 2021 before the market opens on February 24, 2022. The company's management will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss these results along with updates on business developments and future outlook. Audio of the webcast will be accessible in the 'Investors' section of the Nautilus website.

Nautilus is focused on developing a single-molecule protein analysis platform aimed at advancing proteomics and improving healthcare.

Nautilus Biotechnology and Abcam announced a strategic partnership to enhance proteomic analysis through the development of affinity binding reagents. This collaboration will leverage Abcam's monoclonal antibody technologies to support Nautilus in reagent R&D and establish a long-term supply relationship. Initially focused on affinity reagents, it aims for large-scale manufacturing for commercialization. Both companies emphasize the partnership's potential to improve drug and diagnostic tool development, catering to the growing importance of proteomic data.

Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic partnership with Abcam to enhance its reagent development capabilities. This collaboration aims to accelerate R&D by utilizing Abcam's advanced monoclonal antibody technologies. The focus will be on developing affinity binding reagents for Nautilus' proteomic analysis system, followed by large-scale manufacturing and commercialization. This partnership is seen as a significant step toward improving drug and diagnostic tool development, enhancing the overall efficacy of Nautilus’ protein analysis platform.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its third-quarter financial results for 2021, highlighting significant business developments and financial metrics. The company initiated a strategic partnership with Abcam to enhance protein detection and signed two new research collaborations with a global pharmaceutical company and UT MD Anderson Cancer Center. Financially, Nautilus recorded an operating expense of $14.6 million, a 262% increase from the previous year, and a net loss of $14.5 million. However, cash reserves stood strong at $374 million as of September 30, 2021.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report its financial results for Q3 2021 on November 2, 2021. Prior to the market open, the company will hold a webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss its results and business developments. Nautilus is focused on a single-molecule protein analysis platform aimed at revolutionizing proteomics and enhancing human health and medicine.